The invention concerns new keto-ammonium compounds with surfactant properties and improved biodegradability.

The invention concerns new keto-ammonium compounds with surfactant properties and improved biodegradability.

Provided is a production method of kakeromycin and a derivative thereof showing an antifungal activity and cytotoxicity and expected as a new antifungal agent or anticancer agent, by chemical synthesis. A production method of a compound represented by the formula (1):

##STR00001##

wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; and n is 0 or 1, or a salt thereof, including a step of subjecting a compound represented by the formula (2):

##STR00002##

wherein R and n are as defined above, or a salt thereof, to an oxidation reaction.

A method of manufacturing triacetonamine includes (a) introducing an acetone and an ammonia into a first reactor in the presence of a first acidic catalyst to form an acetonin; (b) introducing the acetonin and water into a second reactor in the presence of a second acidic catalyst to form a triacetonamine and side products, wherein the side products include diacetone alcohol, diacetone amine, mesityl oxide, 2,2,4,6-tetramethyl-2,3-dihydropyridine, or a combination thereof; (c) separating the triacetonamine and the side products by distillation under reduced pressure; (d) introducing the side products and water into a third reactor to heat and crack the side products in the presence of an amphiphilic catalyst to form acetone; and (e) introducing the acetone obtained from step (d) into the first reactor.

A method of manufacturing triacetonamine includes (a) introducing an acetone and an ammonia into a first reactor in the presence of a first acidic catalyst to form an acetonin; (b) introducing the acetonin and water into a second reactor in the presence of a second acidic catalyst to form a triacetonamine and side products, wherein the side products include diacetone alcohol, diacetone amine, mesityl oxide, 2,2,4,6-tetramethyl-2,3-dihydropyridine, or a combination thereof; (c) separating the triacetonamine and the side products by distillation under reduced pressure; (d) introducing the side products and water into a third reactor to heat and crack the side products in the presence of an amphiphilic catalyst to form acetone; and (e) introducing the acetone obtained from step (d) into the first reactor.

The present invention discloses a process for synthesis of piperidine alkaloids selected from fagomine, 4-epi-fagomine and nojirimycin from tri-O-benzyl-D-glucal or tri-O-benzyl-D-galactal.

The present invention discloses a process for synthesis of piperidine alkaloids selected from fagomine, 4-epi-fagomine and nojirimycin from tri-O-benzyl-D-glucal or tri-O-benzyl-D-galactal.

The present invention relates to: a cyclohexene derivative; a preparation method therefor; and a pharmaceutical composition for preventing or treating metabolic diseases, containing the same as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (cAMP) by activating G protein-coupled receptor 119 (GPR-119) and simultaneously exhibits weight loss and hypoglycemic effects by inducing the release of glucagon-like peptide-1 (GLP-1), which is a neuroendocrine protein, and thus can be useful as a pharmaceutical composition for preventing or treating metabolic diseases such as obesity, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome X.

The present invention relates to: a cyclohexene derivative; a preparation method therefor; and a pharmaceutical composition for preventing or treating metabolic diseases, containing the same as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (cAMP) by activating G protein-coupled receptor 119 (GPR-119) and simultaneously exhibits weight loss and hypoglycemic effects by inducing the release of glucagon-like peptide-1 (GLP-1), which is a neuroendocrine protein, and thus can be useful as a pharmaceutical composition for preventing or treating metabolic diseases such as obesity, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome X.

An N-methyl-substituted triacetonamine compound is prepared by reacting at least one triacetonamine compound (I) with formaldehyde under reductive conditions, in the presence of hydrogen and in the presence of a supported catalyst, wherein the supported catalyst contains at least one metal M, wherein the metal M is selected from the group consisting of V, Cr, Mo, Mn, Ni, Pd, Pt, Fe, Ru, Os, Co, Rh, Ir, and Cu.